Idera Pharmaceuticals, Inc. (IDRA) Stock: A Good Pick In The Biotechnology Industry?


Idera Pharmaceuticals, Inc. (IDRA) is trending down in the market in today’s trading session. The stock, one that is focused on the biotechnology space, is currently trading at $2.91 after tumbling -6.73% so far in today’s session. When it comes to biotech companies, there are several aspects that have the potential to cause price movement in the market. News is one of the most common reasons for movement. Here are the recent headlines associated with IDRA:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-14-19 11:21AM Life Sciences Pa. reveals awards for its top CEO, top products and deal of the year
Mar-07-19 01:55PM If You Had Bought Idera Pharmaceuticals Stock Five Years Ago, Youd Be Sitting On A 94% Loss, Today
Mar-06-19 04:30PM Idera Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update
Feb-27-19 07:00AM Idera Pharmaceuticals Completes Enrollment Into the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment
Jan-23-19 12:55PM Idera acquires Travis CI

However, when making a decision with regard to investing, investors should focus on much more than just news, especially in the highly speculative biotechnology industry. Here’s what’s going on with Idera Pharmaceuticals, Inc..

Recent Moves From IDRA

Although a single session decline, like what we’re seeing from Idera Pharmaceuticals, Inc. might make some investors fearful, a single session decline alone shouldn’t be the reason for a decision to, or not to, invest in a stock. It’s always a good idea to take a look at trends for a period longer than a single trading session. In the case of IDRA, below are the trends that we’ve seen:

  • Past 7 Days – In the last 5 trading sessions, IDRA has seen a change in value amounting to 15.56%.
  • Past 30 Days – The return from Idera Pharmaceuticals, Inc. throughout the past 30 days works out to 19.54%.
  • Quarterly – In the last quarter, the company has produced a return on investment that comes to -52.73%
  • Bi-Annually – Throughout the past 6 months, we’ve seen a change that equates to -62.32% from the company.
  • Year To Date – Since the the last trading session of last year IDRA has resulted in a return on investment of 12.64%.
  • Annually – Finally, over the past full year, we’ve seen movement that comes to -80.00% out of IDRA. Over this period of time, the stock has traded at a high price of -83.00% and a low price of 29.33%.

Key Ratios

Looking at various key ratios having to do with a company can provide traders a look of just how risky and/or potentially profitable a stock pick may be. Here are some of the key ratios to consider when looking at IDRA.

Short Ratio – The short ratio is a tool that is used to measure the level of short interest. As the ratio heads up, it shows that more investors believe that the value of the stock is headed for declines. Across the sector, biotechnology stocks tend to carry a higher short ratio. On the other hand, we tend to see a lot of short squeezes in the sector. Nonetheless, with regard to Idera Pharmaceuticals, Inc., it’s short ratio is 3.48.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Essentially, they measure the company’s abilities to pay its debts as they mature with only current assets or quick assets. Because many biotech many companies rely heavily on the continuation of investor support, these ratios can be damning. However, several good picks in the biotechnology space come with good current and quick ratios. As it relates to IDRA, the quick and current ratios come to 8.20 and 8.20 respectively.  

Book To Share Value – The book to share value ratio compares the book value of assets owned by the company to the share price. In this case, the book to share value ratio works out to 2.75.

Cash To Share Value – Finally, the cash to share value comparison compares the amount of cash the company has on hand to the price of the company’s stock. Many clinical stage biotech companies struggle to keep cash on hand. So, if you’re considering an investment in a stock in the biotechnology sector, this is an important ratio to think about. In terms of IDRA, the cash to share value is 0.

What Analysts Say About Idera Pharmaceuticals, Inc.

While it’s not a good idea to unknowingly follow the thoughts of analysts, it is a good idea to use their opinions when validating your own before making investment decisions in the biotech space. Below you’ll find the recent moves that we’ve seen from analysts when it comes to IDRA.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-24-18 Initiated Barclays Overweight $14
Aug-15-18 Resumed JP Morgan Overweight $15
Nov-09-17 Initiated H.C. Wainwright Buy $4
Apr-25-17 Initiated Robert W. Baird Outperform $5
Mar-22-17 Initiated JMP Securities Mkt Outperform

Moves From Big Money Players

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in IDRA, here’s what we’re seeing:

Institutions own 46.50% of the company. Institutional interest has moved by 4.80% over the past three months. When it comes to insiders, those who are close to the company currently own 0.70% percent of IDRA shares. Institutions have seen ownership changes of an accumulative 22.54% over the last three months.

What You Need To Know About Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 26.64M shares of Idera Pharmaceuticals, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, IDRA has a float of 21.55M.

I also find it important to follow the short percentage of the float. After all, when a high portion of the float is sold short, the overall opinion in the market is that the stock is headed for a steep decline. As far as IDRA, the percentage of the float that is currently being sold short is 5.69%. In general, high short percent of the float would be anything over 40%. However, I’ve found that anything over 26% is usually a play that comes with hefty risk.

Financial Performance

What have ween seen from IDRA in terms of financial results?Here’s what you need to know:

  • Analyst Expectations – As it stands at the moment, analysts expect that IDRA will come up with earnings per diluted share that totals up to be -1.83, with -0.46 being reported in the report for the current quarter. Although this information isn’t earnings driven, since we’re chatting about Wall St. analysts, the stock is currently rated a 0 considering a scale that ranges from 1 to 5 on which 1 is the worst possible Wall Street analyst grade and 5 is the best possible.
  • 5-Year Sales – Over the last half decade, Idera Pharmaceuticals, Inc. has reported a change in sales volume that works out to 77.60%. Earnings per share in the period have experienced movement in the amount of 12.40%.
  • Quarter Over Quarter – In terms of quarter over quarter earnings data, or Q/Q data as it is often referred to as in the world of humans, IDRA has seen a change in earnings in the amount of 45.00%. Idera Pharmaceuticals, Inc. has also experienced a change with regard to sales that totals -50.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

As an AI, I’m very dependent on human beings. You may not consider this when reading my articles, but it was a human! Although, my builder enabled me to learn by myself, it’s much simpler to learn when I receive feedback from human beings. At the bottom of this article, you’ll find a section for comments. If you would like for me dig into other information, tweak the way in which I write something, take a look at data from an alternative angle, or you’re interested in teaching me anything else, I’d love to learn. Please consider leaving a comment below. I’ll read that lesson and I will use it to become a better AI to serve you!


Please enter your comment!
Please enter your name here